10-Year Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement or Surgery in Intermediate-Risk Patients

作者：Tamim M. Nazif, Matheus Simonato, Raj R. Makkar, Vinod H. Thourani, Desai Nm, Vasilis Babaliaros, Kevin Greason, Joshua Rovin, Sergio Waxman, Charles Davidson, Dean J. Kereiakes, Anuj Gupta, Lowell Satler, Richard Schwartz, Samir Kapadia, SJ Wong, Richard W. Smalling, Mohammad Ghani, Paul Teirstein, Isaac George, Srinivasa Potluri, Molly Szerlip, Ke Xu, David J. Cohen, Rahul P. Sharma, Philippe Pibarot, Rebecca T. Hahn, Michael J. Mack, Martin B. Leon · 发表于：Journal of the American College of Cardiology · 年份：2026 · DOI：10.1016/j.jacc.2026.03.170 · 被引用次数：4 · 研究领域：Cardiac Valve Diseases and Treatments、Aortic Disease and Treatment Approaches、Cardiovascular Function and Risk Factors

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement for patients with symptomatic severe aortic stenosis. However, long-term outcomes data are lacking for TAVR, particularly with newer-generation transcatheter heart valves. OBJECTIVES: The purpose of this study was to compare 10-year outcomes of intermediate-risk patients who underwent TAVR with the third-generation, balloon-expandable SAPIEN 3 valve in the PARTNER 2 SAPIEN 3 Intermediate-risk Registry (P2S3i) with those who underwent surgery in the PARTNER 2A (P2A) randomized trial. METHODS: Intermediate-risk patients were enrolled in the P2A trial from 2011 through 2013 and in the P2S3i registry in 2014. These prospective, multicenter studies used the same eligibility criteria and stratified patients based on suitability for transfemoral or transthoracic (transapical/transaortic) access. Ten-year outcomes were evaluated, including all-cause mortality, aortic valve reintervention, and core laboratory-adjudicated echocardiographic outcomes. Patient reconsent was required at 5 years for extended 10-year follow-up, and vital status sweeps were implemented to improve data completeness for all-cause mortality. To account for potential baseline differences and reduce confounding, P2S3i TAVR patients were propensity score-matched 1:1 to P2A surgical patients. RESULTS: Among 2,005 patients who received a valve, 1,069 underwent TAVR in P2S3i and 936 underwent surgery in P2A...